 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || MetaBlok (lsalt peptide) / Arch Biopartners
Trial completion date, Trial primary completion date, Surgery: LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery (clinicaltrials.gov) - Nov 1, 2024
P2, N=240, Recruiting, Sponsor: Arch Biopartners Inc.
Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Feb 2025 --> Aug 2025
- | MetaBlok (lsalt peptide) / Arch Biopartners
Journal: Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19). (Pubmed Central) - Mar 20, 2024
P2
Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Feb 2025 --> Aug 2025 In a Phase 2 study, LSALT peptide was demonstrated to be safe and tolerated in patients hospitalised with moderate-to-severe COVID-19.
- |||| MetaBlok (lsalt peptide) / Arch Biopartners
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Surgery: LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery (clinicaltrials.gov) - Mar 18, 2024
P2, N=240, Recruiting, Sponsor: Arch Biopartners Inc.
In a Phase 2 study, LSALT peptide was demonstrated to be safe and tolerated in patients hospitalised with moderate-to-severe COVID-19. Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Jun 2025 | Initiation date: Sep 2023 --> Mar 2024 | Trial primary completion date: Sep 2024 --> Feb 2025
- ||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, MetaBlok (lsalt peptide) / Arch Biopartners
Enrollment closed, Trial primary completion date: CATCO: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (clinicaltrials.gov) - Oct 13, 2023
P3, N=2900, Active, not recruiting, Sponsor: Sunnybrook Health Sciences Centre
Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Jun 2025 | Initiation date: Sep 2023 --> Mar 2024 | Trial primary completion date: Sep 2024 --> Feb 2025 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2023 --> Mar 2024
- ||||| MetaBlok (lsalt peptide) / Arch Biopartners
New P2 trial, Surgery: LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery (clinicaltrials.gov) - May 30, 2023
P2, N=240, Not yet recruiting, Sponsor: Arch Biopartners Inc.
- ||| MetaBlok (lsalt peptide) / Arch Biopartners
Trial completion, Trial completion date: LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) (clinicaltrials.gov) - Apr 25, 2023
P2, N=61, Completed, Sponsor: Arch Biopartners Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2023 --> Mar 2024 Active, not recruiting --> Completed | Trial completion date: Jun 2021 --> Jun 2022
- | MetaBlok (lsalt peptide) / Arch Biopartners
Journal: Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury. (Pubmed Central) - Apr 20, 2022
Renal inflammation and the AKI phenotype were attenuated in Dpep1 mice or mice pretreated with DPEP1 antagonists, including the LSALT peptide, a nonenzymatic DPEP1 inhibitor...DPEP1, CD44, and ICAM-1 all contributed to the recruitment of monocyte/macrophages to the kidney following IRI. These results identify DPEP1 as a major leukocyte adhesion receptor in the kidney and potential therapeutic target for AKI.
- |||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, MetaBlok (lsalt peptide) / Arch Biopartners
Phase classification, Trial completion date, Trial primary completion date: CATCO: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (clinicaltrials.gov) - Apr 4, 2022
P3, N=2900, Recruiting, Sponsor: Sunnybrook Health Sciences Centre
These results identify DPEP1 as a major leukocyte adhesion receptor in the kidney and potential therapeutic target for AKI. Phase classification: P2 --> P3 | Trial completion date: May 2022 --> May 2024 | Trial primary completion date: Mar 2022 --> Mar 2023
- || MetaBlok (lsalt peptide) / Arch Biopartners
Enrollment closed: LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) (clinicaltrials.gov) - May 5, 2021
P2, N=60, Active, not recruiting, Sponsor: Arch Biopartners Inc.
Phase classification: P2 --> P3 | Trial completion date: May 2022 --> May 2024 | Trial primary completion date: Mar 2022 --> Mar 2023 Recruiting --> Active, not recruiting
- ||| MetaBlok (lsalt peptide) / Arch Biopartners
Enrollment open, Trial initiation date: LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) (clinicaltrials.gov) - Nov 4, 2020
P2, N=60, Recruiting, Sponsor: Arch Biopartners Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Jul 2020 --> Oct 2020
- ||| MetaBlok (lsalt peptide) / Arch Biopartners
Trial completion: A Phase I Study to Evaluate LSALT Peptide (clinicaltrials.gov) - Jun 18, 2020
P1, N=52, Completed, Sponsor: Arch Biopartners Inc.
Not yet recruiting --> Recruiting | Initiation date: Jul 2020 --> Oct 2020 Not yet recruiting --> Completed
- ||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, MetaBlok (lsalt peptide) / Arch Biopartners
Enrollment change: CATCO: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (clinicaltrials.gov) - Jun 4, 2020
P2, N=2900, Recruiting, Sponsor: Sunnybrook Health Sciences Centre
Not yet recruiting --> Completed N=440 --> 2900
- |||| MetaBlok (lsalt peptide) / Arch Biopartners
New P2 trial: LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) (clinicaltrials.gov) - May 26, 2020
P2, N=60, Not yet recruiting, Sponsor: Arch Biopartners Inc.
- |||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, MetaBlok (lsalt peptide) / Arch Biopartners
Enrollment open: CATCO: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (clinicaltrials.gov) - Apr 9, 2020
P2, N=440, Recruiting, Sponsor: Sunnybrook Health Sciences Centre
N=440 --> 2900 Active, not recruiting --> Recruiting
- ||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, MetaBlok (lsalt peptide) / Arch Biopartners
New P2 trial: CATCO: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (clinicaltrials.gov) - Apr 1, 2020
P2, N=440, Active, not recruiting, Sponsor: Sunnybrook Health Sciences Centre
- | MetaBlok (lsalt peptide) / Arch Biopartners
New P1 trial: A Phase I Study to Evaluate LSALT Peptide (clinicaltrials.gov) - Dec 11, 2018
P1, N=40, Not yet recruiting, Sponsor: Arch Biopartners Inc.